Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication

Widschwendter, Christian G.; Kemmler, Georg; Rettenbacher, Maria A.; Yalcin-Siedentopf, Nursen; Hofer, Alex

doi:10.1186/s12888-018-1791-y

Cited by 13 publications

(21 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies also provide empirical evidence in the same direction. A study of 30 patients with schizophrenia showed that the attitude towards medication did not change, despite improvement of their psychopathological symptoms [34]. A negative attitude towards medication is not only a psychiatric phenomenon but also a problem in the treatment of chronic physical diseases such as diabetes and high blood pressure [35,36].…”

Section: Discussionmentioning

confidence: 99%

Patients’ perception of coercion with respect to antipsychotic treatment of psychotic disorders and its predictors

Hirsch¹,

Thilo²,

Steinert³

et al. 2021

Soc Psychiatry Psychiatr Epidemiol

View full text Add to dashboard Cite

Purpose The present study investigates perceived coercion in psychiatric inpatients under prescribed antipsychotic medication without a court order. The objective of this study was to investigate whether and to what extent involuntary and voluntary inpatients feel coerced to take their medication and which factors affect perceived coercion. Methods Voluntarily and involuntarily admitted patients (55 and 36, respectively) were interviewed about the extent of perceived coercion. In addition, socio-demographic and clinical data were collected. The Admission Experience Scale (aAES) was used to assess perceived coercion concerning medication. To measure insight into illness, attitude towards medication, and symptom severity, we used a questionnaire on insight into illness (FKE-10), the Drug Attitude Inventory (DAI-10), and the Brief Psychiatric Rating Scale (BPRS-24), respectively. Results Voluntarily treated patients experienced significantly less coercion when taking prescribed medication in inpatient settings than involuntarily treated patients. The experience of coercion was not related to socio-demographic or clinical variables nor to the BPRS-24 score, but to insight into illness and attitude towards medication. Patients who had experienced at least one coercive measure during the index hospital stay showed a higher level of perceived coercion. Conclusion Perceived coercion related to medication is dependent on insight into illness and experience of previous coercive interventions rather than on the severity of psychopathological symptoms. These findings are very similar to a previous study in a forensic psychiatric sample. Having experience of at least one coercive measure seems to be a decisive aspect of the extent of the patients’ perceived coercion.

show abstract

Section: Discussionmentioning

confidence: 99%

Patients’ perception of coercion with respect to antipsychotic treatment of psychotic disorders and its predictors

Hirsch¹,

Thilo²,

Steinert³

et al. 2021

Soc Psychiatry Psychiatr Epidemiol

View full text Add to dashboard Cite

show abstract

“…This is consistent with the literature that patients’ perceived subjective well-being and treatment response may influence medication preference and attitude. 36 Thus the assessment of subjective well-being is helpful for selecting the optimal drug for the individual patient. 37 This reinforces the need to involve the patient in decision-making regarding their care.…”

Section: Discussionmentioning

confidence: 99%

Attitude and preferences towards oral and long-acting injectable antipsychotics in patients with psychosis in KwaZulu-Natal, South Africa

Roopun

Tomita

Paruk

2020

South African Journal of Psychiatry

View full text Add to dashboard Cite

Background: Patient attitudes to and satisfaction with their treatment are associated with improved adherence. There is a paucity of data on patient drug attitudes and preference to oral compared to long-acting injectable (LAI) antipsychotic treatment.Aim: To describe patients attitudes and preferences towards oral versus LAI antipsychotic formulations and explore factors associated with their drug attitudes.Setting: Two psychiatric hospitals in KwaZulu-Natal, South Africa.Method: A cross–sectional survey of 140 adult outpatients with schizophrenia spectrum disorders receiving LAI with or without oral antipsychotics (a total of 70) were compared to patients receiving oral antipsychotics only (N = 70). A sociodemographic-clinical questionnaire, chart review and the Drug Attitude Inventory scale (DAI–30) were used.Results: Of the 140 participants, 98 (70%) preferred the medication formulation currently prescribed, and 132 (94.3%) reported a positive drug attitude towards their antipsychotic medication. The adjusted regression analysis indicated that study participants who were currently on a formulation that matched their preference scored better on the DAI-30 than individuals with a mismatch in use and preference (p 0.04). In terms of covariates, we found, on one hand, that study participants who are divorced (compared to single) with schizophrenia diagnosis (compared to other psychotic or schizoaffective disorder) are more likely to have lower score on DAI-30. On the other hand, we found that study participants with a higher household income and longer duration of the psychotic illness were associated with greater DAI-30 score.Conclusion: The majority of participants preferred their current oral and LAI formulation. Drug attitude was influenced by several factors, including matched medication use. Focused psychoeducation should be considered for newly diagnosed, lower socio-economic groups and patients with non-affective psychosis to improve drug attitude.

show abstract

“…This result is to be expected, since the study considers patients who have received community and outpatient treatment in mental health services. 10 However, a previous study (part of the larger International Research Project) showed a difference between the countries involved in this research where patients in Chile reported greater adherence to medication. 13 This last point can be explained by the Mental health policies in Chile, where there is a program Garantías Explícitas en Salud (GES) (Explicit Health Guarantees) that constitute a set of benefits guaranteed by law for individuals diagnosed with schizophrenia and other disorders, which ensures the delivery of antipsychotic medication to the patient, unlike Peru and Bolivia, where access to medication is not universal for the population of patients diagnosed with schizophrenia.…”

Section: Discussionmentioning

confidence: 75%

“…[7][8][9] Among the most important risk factors for relapse, re-hospitalization, and resistance to treatment in patients diagnosed with schizophrenia, non-adherence to pharmacological treatment stands out, which is also associated with substance abuse, suicide attempts, violence, and the deterioration of long-term functioning in these patients. 10,11 Non-adherence is considered a complex phenomenon, which could be influenced by four factors: sociodemographic variables, psychotic symptomatology (including persecutory delusion, hostility, and cognitive impairment), variables related to treatment (frequency and intensity of side effects, subjective feeling under treatment, comorbid addiction, duration of treatment, and addictive behavior), and insight into the disorder. [12][13][14][15] Quality of life (QoL) is severely impaired in patients diagnosed with schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

<p>Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia</p>

Caqueo-Urízar¹,

Urzúa²,

Mena-Chamorro³

et al. 2020

PPA

View full text Add to dashboard Cite

The purpose of this study was to describe the association between adherence to antipsychotic medication and quality of life (QoL) in a sample of individuals diagnosed with schizophrenia. Methods: Two hundred fifty-three patients were included from three public mental health services from Bolivia, Peru, and Chile. Data were collected using the Drug Attitude Inventory (DAI-10) and the Schizophrenia Quality of Life short-version questionnaire (SQoL-18), which considers 8 dimensions. Results: Significant associations were found between adherence to antipsychotic medication treatment and QoL (S-QoL-18 index: β = 0.26, p = 0.004; self-esteem: β = 0.37, p = 0.000; and sentimental life: β = 0.20, p = 0.033). Associations of clinical and socio-demographic variables with QoL were identified: severity of psychotic symptoms, awareness of the disease, gender, age, and ethnicity were found to be associated with a lower level of QoL (β from 0.14 −0.56). Conclusion: This study provides evidence of the association between adherence to treatment and quality of life in patients diagnosed with schizophrenia. Therefore, as in developed countries, improving adherence to antipsychotic medication would appear to be an important issue to address to improve patients' QoL in Latin American countries.

show abstract

Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication

Cited by 13 publications

References 49 publications

Patients’ perception of coercion with respect to antipsychotic treatment of psychotic disorders and its predictors

Patients’ perception of coercion with respect to antipsychotic treatment of psychotic disorders and its predictors

Attitude and preferences towards oral and long-acting injectable antipsychotics in patients with psychosis in KwaZulu-Natal, South Africa

<p>Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia</p>

Contact Info

Product

Resources

About